broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K38852836-001-02-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.177893 | 1.827916 | 0.918399 | 0.462421 | 0.004389 | 0.005583 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000940 |
BRD-K39974922-001-04-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.408682 | 0.731913 | 0.664049 | 0.731836 | 0.126022 | 1.286251 | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000940 |
BRD-K41859756-001-06-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.195499 | 7.609987 | 0.83443 | 0.489959 | 0.005331 | 0.00569 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000940 |
BRD-K42495768-001-01-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | -0.00748 | 1.45725 | 0.524516 | 0.881002 | 3.667026 | 3.629849 | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000940 |
BRD-K42805893-001-04-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.976081 | 0.65531 | 0.010025 | 0.98704 | 0.050226 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000940 |
BRD-K42828737-001-03-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.767063 | 7.478094 | 0.198363 | 0.903066 | 0.078448 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000940 |
BRD-K42898655-001-01-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.273495 | 0.436412 | 0.733161 | 0.445245 | 0.000145 | 0.000891 | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000940 |
BRD-K43389675-001-02-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.07066 | 2.064725 | 0.758107 | 0.614567 | 0.178674 | 0.192358 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000940 |
BRD-K44227013-001-06-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.225051 | 2.035792 | 0.879426 | 0.599973 | 0.06674 | 0.089529 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000940 |
BRD-K44408410-001-17-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | -0.146445 | 0.556987 | 0.518699 | 0.714585 | 1.487015 | 0.937588 | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000940 |
BRD-K44827188-001-06-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.828052 | 1.307755 | -0.092406 | 0.888527 | 0.018361 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000940 |
BRD-K46386702-001-02-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.963032 | 2.368288 | 0.102334 | 0.97104 | 0.004978 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000940 |
BRD-K49328571-001-15-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.361621 | 2.741233 | 0.544986 | 0.847381 | 0.983241 | 1.571032 | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000940 |
BRD-K49350383-001-14-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.701905 | 1.314429 | 0.207731 | 1 | 2.803713 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000940 |
BRD-K50010139-001-01-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.072519 | 0.8025 | 0.456853 | 0.617866 | 0.190652 | 0.231764 | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000940 |
BRD-K50168500-001-07-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.273062 | 0.491436 | 0.530801 | 0.619612 | 0.059513 | 0.296953 | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000940 |
BRD-K51313569-001-07-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.316543 | 2.936937 | 0.29542 | 0.973821 | 7.925655 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000940 |
BRD-K51791723-003-01-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.112976 | 1.505213 | 0.707756 | 0.658058 | 0.237831 | 0.281948 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000940 |
BRD-K51967704-001-03-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.157223 | 2.104124 | 0.816612 | 0.671074 | 0.226534 | 0.271054 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000940 |
BRD-K52313696-001-12-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.321464 | 2.880199 | 0.518532 | 0.916563 | 3.06666 | 4.384793 | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000940 |
BRD-K53414658-001-08-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.181913 | 1.26017 | 0.392732 | 0.830196 | 1.424072 | 2.038931 | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000940 |
BRD-K53972329-001-07-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.385382 | 1.951783 | 0.308129 | 0.908766 | 2.444365 | 5.199179 | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000940 |
BRD-K54256913-001-08-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.064462 | 6.527025 | 0.681937 | 0.832718 | 1.763525 | 1.801228 | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000940 |
BRD-K54955827-001-02-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.054525 | 0.651951 | -0.199744 | 1 | 0.143013 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000940 |
BRD-K54997624-001-06-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.059107 | 1.555092 | 0.589431 | 0.846202 | 2.166879 | 2.34946 | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000940 |
BRD-K55187425-236-05-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.152177 | 1.599172 | 0.887076 | 0.443084 | 0.016989 | 0.021317 | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000940 |
BRD-K56981171-001-02-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.464067 | 0.508241 | -0.561666 | 0.859167 | 1.389244 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000940 |
BRD-K57080016-001-15-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.481461 | 1.374014 | 0.358811 | 0.88843 | 1.293057 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000940 |
BRD-K57169635-001-04-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.732459 | -1.110496 | -0.059291 | 0.950025 | 0.003285 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000940 |
BRD-K58435339-001-03-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.261573 | 3.656883 | 0.894507 | 0.587839 | 0.044415 | 0.054385 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000940 |
BRD-K58529924-001-01-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.213984 | 3.550368 | 0.631414 | 0.884729 | 2.557637 | 2.993396 | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000940 |
BRD-K58550667-001-08-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.15198 | 2.545808 | 0.704879 | 0.690469 | 0.018089 | 0.020856 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000940 |
BRD-K59317601-001-05-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.109647 | 0.839262 | 0.944068 | 0.285456 | 0.003182 | 0.004274 | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000940 |
BRD-K59369769-001-22-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.270138 | 1.77404 | 0.712022 | 0.715751 | 0.228489 | 0.354087 | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000940 |
BRD-K60866521-001-07-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.942881 | -1.129178 | -0.027382 | 0.976252 | 0.034217 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000940 |
BRD-K60997853-001-02-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.102505 | 1.954544 | 0.73022 | 0.762711 | 0.771195 | 0.867249 | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000940 |
BRD-K61192372-001-08-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.807831 | -0.193814 | 0.05559 | 0.895899 | 0.197046 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000940 |
BRD-K62008436-001-23-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.146997 | 1.12304 | 0.789569 | 0.402565 | 0.000674 | 0.000919 | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000940 |
BRD-K62196610-001-01-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.65396 | 0.403828 | 0.024199 | 0.813872 | 0.0479 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000940 |
BRD-K62200014-003-10-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.587402 | -1.156768 | 0.657291 | 0.87435 | 0.011389 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000940 |
BRD-K62391742-001-09-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.527048 | -0.102181 | -0.308129 | 0.776617 | 0.025818 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000940 |
BRD-K62627508-001-01-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.976046 | -0.171679 | -0.010925 | 0.981376 | 165.073764 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000940 |
BRD-K63504947-001-14-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.12728 | -0.069856 | -0.050595 | 1 | 167,888.299339 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000940 |
BRD-K64881305-001-03-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.623095 | 0.919902 | 0.625097 | 0.821818 | 0.102381 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000940 |
BRD-K66175015-001-12-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.728447 | 4.294223 | 0.334121 | 0.835376 | 0.027857 | null | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000940 |
BRD-K67844266-003-01-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.317284 | 0.554087 | 0.452945 | 0.772304 | 0.51871 | 3.191237 | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000940 |
BRD-K69001009-001-02-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.112784 | 0.864312 | 0.856695 | 0.671849 | 0.289527 | 0.389165 | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000940 |
BRD-K69694239-001-02-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.291857 | 4.105678 | 0.740064 | 0.702052 | 0.168537 | 0.208639 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000940 |
BRD-K69776681-001-03-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.209511 | 4.464868 | 0.603133 | 0.447498 | 0.011329 | 0.012795 | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000940 |
BRD-K70301465-001-05-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.120644 | -7.227379 | 0.059496 | 1 | 0.020979 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000940 |
BRD-K70401845-001-15-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.252595 | 4.465532 | 0.434489 | 0.885224 | 2.253704 | 2.638327 | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000940 |
BRD-K73838513-003-05-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.621972 | 1.236135 | 0.349587 | 0.912714 | 1.120835 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000940 |
BRD-K74514084-003-09-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.48589 | 1.5585 | 0.631693 | 0.731885 | 0.063372 | 0.62529 | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000940 |
BRD-K75009076-001-02-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.096434 | 3.155424 | 0.411876 | 0.905858 | 3.686897 | 3.946011 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000940 |
BRD-K76210423-001-01-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.822591 | 0.722402 | 0.075886 | 0.917621 | 0.112814 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000940 |
BRD-K76239644-001-02-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | -0.168579 | 0.632227 | 0.633828 | 0.720867 | 1.469524 | 0.928094 | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000940 |
BRD-K76674262-001-03-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.130156 | 1.487543 | 0.776655 | 0.470538 | 0.02714 | 0.033238 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000940 |
BRD-K76908866-001-07-6 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.027251 | -0.099305 | -0.003963 | 1 | 4.073656 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000940 |
BRD-K77625799-001-07-7 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.204237 | 2.641024 | 0.753601 | 0.799981 | 0.872734 | 1.064687 | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000940 |
BRD-K78431006-001-15-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | -0.213097 | 1.009667 | 0.506322 | 0.856157 | 4.58767 | 3.227666 | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000940 |
BRD-K79254416-001-21-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.487932 | 0.436345 | 0.337374 | 0.740815 | 0.072382 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000940 |
BRD-K81016934-001-02-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.907913 | 0.166841 | -0.027433 | 0.928112 | 0.000027 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000940 |
BRD-K81418486-001-44-2 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.486221 | 1.251576 | 0.571139 | 0.821307 | 0.346039 | 6.100314 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000940 |
BRD-K81473043-001-19-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.13007 | 6.853803 | 0.820009 | 0.732687 | 0.031674 | 0.033098 | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000940 |
BRD-K82135108-001-04-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.19224 | 6.790199 | 0.963857 | 0.722061 | 0.023179 | 0.024896 | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000940 |
BRD-K82746043-001-19-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.157313 | 4.001005 | 0.620093 | 0.772888 | 0.731325 | 0.80375 | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000940 |
BRD-K82818427-001-04-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.591348 | 1.820118 | 0.442244 | 0.884882 | 0.652189 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000940 |
BRD-K83029223-001-01-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.485399 | 4.760813 | 0.74891 | 0.768551 | 0.007946 | 0.016691 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000940 |
BRD-K83988098-001-02-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.103574 | 2.016754 | 0.609585 | 0.732458 | 0.008628 | 0.009681 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000940 |
BRD-K85402309-043-01-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.209741 | 0.833627 | 0.858462 | 0.765009 | 0.245794 | 0.471946 | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-000940 |
BRD-K85606544-001-09-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.531004 | 0.296907 | -0.038706 | 0.780873 | 0.13085 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-000940 |
BRD-K86972824-001-01-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.570141 | 3.444995 | 0.003335 | 0.953284 | 3.510258 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-000940 |
BRD-K87737963-001-06-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.065868 | 1.897091 | 0.652684 | 0.880184 | 3.034454 | 3.269003 | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-000940 |
BRD-K87782578-001-01-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.211287 | 0.362301 | 0.458473 | 0.728271 | 0.701002 | 3.191688 | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-000940 |
BRD-K87909389-003-03-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.189676 | 3.974024 | 0.912648 | 0.570169 | 0.058124 | 0.065537 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000940 |
BRD-K88510285-001-17-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.173967 | 2.293357 | 0.69105 | 0.6952 | 0.069716 | 0.084006 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-000940 |
BRD-K89014967-001-04-3 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.241591 | 0.52524 | 0.54252 | 0.654072 | 0.128617 | 0.451923 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-000940 |
BRD-K92441787-001-04-1 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.912958 | -3.82146 | 0.118984 | 0.933101 | 1.058538 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-000940 |
BRD-K92723993-001-17-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 1.027168 | -0.007944 | -0.000695 | 1 | 6,411,195,058,433,092,000 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-000940 |
BRD-K95142244-001-01-5 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.659253 | 1.705207 | 0.372202 | 0.830526 | 0.080131 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-000940 |
BRD-K96123349-236-02-8 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.871112 | 6.050384 | 0.150559 | 0.933624 | 0.06753 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-000940 |
BRD-K98572433-001-02-9 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.054422 | 0.730661 | 0.298458 | 0.74251 | 0.875004 | 1.024476 | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-000940 |
BRD-K99113996-001-02-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.191452 | 0.689596 | 0.83251 | 0.501031 | 0.022841 | 0.045998 | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-000940 |
BRD-K99749624-001-07-0 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.287702 | 4.032316 | 0.621203 | 0.918258 | 3.292663 | 4.072006 | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-000940 |
BRD-M97302542-001-04-4 | ACH-000940 | AN3CA_ENDOMETRIUM | MTS010 | 1 | 0.804384 | 3.417689 | 0.072361 | 0.882089 | 0.028809 | null | dichloroacetate | pyruvate dehydrogenase kinase inhibitor | PDK1 | null | null | [Na].OC(=O)C(Cl)Cl, [Na].OC(=O)C(Cl)Cl | Phase 3 | true | ACH-000940 |
BRD-A70858459-001-01-7 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.993896 | 0.047586 | -0.020433 | 0.996949 | 0.078749 | null | estramustine | DNA alkylating agent | ESR1, ESR2, MAP1A, MAP2 | oncology | prostate cancer | C[C@]12CCC3C(CCc4cc(OC(=O)N(CCCl)CCCl)ccc34)C1CC[C@@H]2O | Launched | true | ACH-000941 |
BRD-A74914197-001-02-9 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 2.250481 | 1.146667 | 0.477223 | 1 | 0.011064 | null | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-000941 |
BRD-K02113016-001-19-6 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.470735 | 6.591043 | 0.268493 | 1 | 0.816275 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-000941 |
BRD-K02130563-001-11-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.274129 | 4.627059 | 0.443048 | 0.796373 | 0.657159 | 0.780289 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-000941 |
BRD-K03390685-001-01-7 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.067228 | 0.018276 | -0.002169 | 1 | 0.03489 | null | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-000941 |
BRD-K03406345-001-21-1 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.832331 | -2.774017 | -0.109349 | 0.927334 | 0.040918 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-000941 |
BRD-K03449891-001-08-6 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.868273 | -0.893157 | 0.048561 | 0.939527 | 0.027308 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000941 |
BRD-K03765900-001-01-9 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.333181 | 0.781049 | 0.385385 | 0.737166 | 0.230058 | 0.938003 | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000941 |
BRD-K05804044-001-18-5 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.136409 | 1.393822 | 0.111558 | 1 | 0.143084 | null | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000941 |
BRD-K06814349-304-02-7 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.570855 | 2.225192 | 0.493329 | 1 | 1.117783 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000941 |
BRD-K08109215-001-06-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.54274 | 0.855665 | 0.521328 | 0.804656 | 0.162149 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000941 |
BRD-K08542803-001-02-3 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.079633 | 7.548937 | 0.769059 | 0.758409 | 0.782839 | 0.801034 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000941 |
BRD-K08547377-001-04-4 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.90349 | 1.44895 | 0.590595 | 1 | 0.017221 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000941 |
BRD-K08703257-001-13-9 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 1.154394 | -0.823991 | 0.137991 | 1 | 0.040179 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000941 |
BRD-K08799216-001-05-3 | ACH-000941 | HEC1B_ENDOMETRIUM | MTS010 | 1 | 0.557873 | 1.311717 | -0.047028 | 0.879399 | 0.725701 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-000941 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.